Aileron Therapeutics Inc. (ALRN): Here Are Some Research Recommendations

0
9
MDVL Stock
MDVL Stock

Aileron Therapeutics Inc. (NASDAQ:ALRN) traded with a subtraction of -$0.02 to $0.21 on Thursday, a downside of -8.81 percent. An average of 1,049,869 shares of common stock have been traded in the last five days. There was a fall of -$0.0695 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 1,554,302 shares traded, while the 50-day average volume stands at 1,374,445.

ALRN stock has increased by 15.75% in the last month. The company shares reached their 1-month lowest point of $0.1634 on 09/01/22. With the stock rallying to its 52-week high on 04/06/22, shares of the company touched a low of $0.13 and a high of $1.12 in 52 weeks. It has reached a new high 4 times so far this year and lost -58.87% or -$0.3524 in price. In spite of this, the price is down -81.15% from the 52-week high.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Valuation Metrics

Aileron Therapeutics Inc. (ALRN) stock’s beta is 2.17. Other valuation ratios to consider include the price-to-book (PB) ratio at 0.72.

Financial Health

The quick ratio of Aileron Therapeutics Inc. for the three months ended June 29 was 6.50, and the current ratio was 6.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Aileron Therapeutics Inc.’s return on assets was -67.50%.

Earnings Surprise

For the three-month period that ended June 29, Aileron Therapeutics Inc. had $24.75 million in cash. The company posted a net income of -$7.99 million in the quarter, while revenues of -$8.42 million were grew 28.79%. The analyst consensus anticipated Aileron Therapeutics Inc.’s latest quarter earnings to come in at -$0.09 per share, but it turned out to be -$0.09, a 0.00% surprise. Shareholders own equity worth $90.82 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Aileron Therapeutics Inc. (ALRN) price momentum. RSI 9-day as of the close on 21 September was 45.07%, suggesting the stock is Neutral, with historical volatility in this time frame at 189.07%.

As of today, ALRN’s price is $0.2425 -24.82% or -$0.0695 from its 5-day moving average. ALRN is currently trading +0.72% higher than its 20-day SMA and -52.38% lower than its 100-day SMA. However, the stock’s current price level is -16.04% below the SMA50 and -62.26% below the SMA200.

The stochastic %K and %D were 40.73% and 50.42%, respectively, and the average true range (ATR) was 0.0315. With the 14-day stochastic at 29.12% and the average true range at 0.0303, the RSI (14) stands at 47.84%. The stock has reached -0.0118 on the 9-day MACD Oscillator while the 14-day reading was at 0.0103.

Analyst Ratings

William Blair launched coverage on Aileron Therapeutics Inc. (NASDAQ: ALRN) in its analyst report released on July 24, 2017. The firm assigned the stock an Outperform rating. The consensus rating for Aileron Therapeutics Inc. (ALRN) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ALRN, while 3 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.

What is ALRN’s price target for the next 12 months?

Analysts predict a range of price targets between $2.00 and $2.00, with a median target of $2.00. Taking a look at these predictions, the average price target given by analysts for Aileron Therapeutics Inc. (ALRN) stock is $2.00.

LEAVE A REPLY

Please enter your comment!
Please enter your name here